Cheng Chi-Fung, Lin Ying-Ju, Tsai Fuu-Jen, Li Te-Mao, Lin Ting-Hsu, Liao Chiu-Chu, Huang Shao-Mei, Liu Xiang, Li Ming-Ju, Ban Bo, Liang Wen-Miin, Lin Jeff Chien-Fu
Genetic Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Graduate Institute of Biostatistics, School of Public Health, China Medical University, Taichung, Taiwan.
Front Pharmacol. 2019 Jun 11;10:629. doi: 10.3389/fphar.2019.00629. eCollection 2019.
Hip fracture is a major public health concern, with high incidence rates in the elderly worldwide. Hip fractures are associated with increased medical costs, patient dependency on families, and higher rates of morbidity and mortality. Chinese herbal medicine (CHM) is typically characterized as cost-effective and suitable for long-term use with few side effects. To better understand the effects of CHM on hip fracture patients, we utilized a population-based database to investigate the demographic characteristics, cumulative incidence of overall mortality, readmission, reoperation, and patterns of CHM prescription. We found that CHM usage was associated with a lower risk of overall mortality [ = 0.0009; adjusted hazard ratio (HR): 0.47, 95% confidence interval (CI): 0.30-0.73], readmission ( = 0.0345; adjusted HR: 0.67, 95% CI: 0.46-0.97), and reoperation ( = 0.0009; adjusted HR: 0.57, 95% CI: 0.40-0.79) after adjustment for age, type of hip fracture, surgical treatment type, and comorbidities. We also identified the herbal formulas, single herbs, and prescription patterns for the treatment of hip fracture by using association rule mining and network analysis. For hip fracture patients, the most common CHM coprescription pattern was Du-Zhong (DZ) → Xu-Duan (XD), followed by Du-Huo-Ji-Sheng-Tang (DHJST) → Shu-Jing-Huo-Xue-Tang (SJHXT), and Gu-Sui-Bu (GSB) → Xu-Duan (XD). Furthermore, XD was the core prescription, and DZ, GSB, SJHXT, and DHJST were important prescriptions located in cluster 1 of the prescription patterns. This study provides evidence for clinical CHM use as an adjunctive therapy that offers benefits to hip fracture patients.
髋部骨折是一个重大的公共卫生问题,在全球老年人中发病率很高。髋部骨折与医疗费用增加、患者对家庭的依赖以及更高的发病率和死亡率相关。中药通常具有成本效益高、适合长期使用且副作用少的特点。为了更好地了解中药对髋部骨折患者的影响,我们利用一个基于人群的数据库来调查人口统计学特征、总死亡率、再入院率、再次手术率的累积发生率以及中药处方模式。我们发现,在对年龄、髋部骨折类型、手术治疗类型和合并症进行调整后,使用中药与较低的总死亡率风险[P = 0.0009;调整后的风险比(HR):0.47,95%置信区间(CI):0.30 - 0.73]、再入院率(P = 0.0345;调整后的HR:0.67,95%CI:0.46 - 0.97)和再次手术率(P = 0.0009;调整后的HR:0.57,95%CI:0.40 - 0.79)相关。我们还通过关联规则挖掘和网络分析确定了治疗髋部骨折的中药配方、单味药和处方模式。对于髋部骨折患者,最常见的中药联合处方模式是杜仲(DZ)→续断(XD),其次是独活寄生汤(DHJST)→舒筋活血汤(SJHXT),以及骨碎补(GSB)→续断(XD)。此外,XD是核心处方,DZ、GSB、SJHXT和DHJST是位于处方模式聚类1中的重要处方。本研究为临床使用中药作为辅助治疗为髋部骨折患者带来益处提供了证据。